Session » Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization (2639–2644)
- 9:30AM-9:45AM
-
Abstract Number: 2639
Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis
- 9:45AM-10:00AM
-
Abstract Number: 2640
Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study
- 10:00AM-10:15AM
-
Abstract Number: 2641
Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases
- 10:15AM-10:30AM
-
Abstract Number: 2642
Impact of Rheumatoid Arthritis Therapeutic Classes on Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism: A Population-Based Cohort Study
- 10:30AM-10:45AM
-
Abstract Number: 2643
Microbiome Signatures in RA Treatment: Personalizing Methotrexate Therapy
- 10:45AM-11:00AM
-
Abstract Number: 2644
Single Cell RNA-seq Profiling Reveals a Blood Monocyte Phenotype Associated with Response to TNF Inhibitor Therapy in RA Patients